WallStSmart

Rezolve AI Limited Ordinary Shares (RZLV)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zepp Health Corp generates 453% more annual revenue ($258.90M vs $46.80M). ZEPP leads profitability with a -15.5% profit margin vs -216.7%. ZEPP earns a higher WallStSmart Score of 38/100 (F).

RZLV

Avoid

26

out of 100

Grade: F

Growth: 6.3Profit: 2.0Value: 5.0Quality: 5.0

ZEPP

Hold

38

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for RZLV.

ZEPPUndervalued (+48.9%)

Margin of Safety

+48.9%

Fair Value

$46.96

Current Price

$18.01

$28.95 discount

UndervaluedFair: $46.96Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

RZLV1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
4888.0%10/10

Revenue surging 4888.0% year-over-year

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

RZLV4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.06B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-98.7%2/10

ROE of -98.7% — below average capital efficiency

Free Cash FlowQuality
$-67.24M2/10

Negative free cash flow — burning cash

ZEPP4 concerns · Avg: 2.3/10
Market CapQuality
$270.28M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Free Cash FlowQuality
$-26.48M2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : RZLV

The strongest argument for RZLV centers on Revenue Growth. Revenue growth of 4888.0% demonstrates continued momentum.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : RZLV

The primary concerns for RZLV are EPS Growth, Market Cap, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

RZLV is growing revenue faster at 4888.0% — sustainability is the question.

ZEPP generates stronger free cash flow (-26M), providing more financial flexibility.

Monitor SOFTWARE - INFRASTRUCTURE industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (38/100 vs 26/100) and 43.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Rezolve AI Limited Ordinary Shares

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Rezolve AI Limited is an innovative technology firm at the forefront of artificial intelligence solutions specifically designed to transform consumer engagement and marketing strategies. By harnessing sophisticated machine learning algorithms, the company empowers businesses to enhance their operational effectiveness while delivering personalized customer experiences. Rezolve AI’s strong emphasis on innovation and scalability positions it to redefine customer interactions in an evolving digital landscape, aligning its offerings with the surging demand for advanced analytics and digital commerce solutions. As a result, Rezolve AI is emerging as a key player in the rapidly expanding AI market, poised for significant growth and impact.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?